Skip to main content
. Author manuscript; available in PMC: 2016 Jan 30.
Published in final edited form as: Circ Res. 2014 Nov 5;116(3):448–455. doi: 10.1161/CIRCRESAHA.116.305360

Figure 2. Comparative Prognostic Value of Plasma TMAO and Cystatin C in the Non-CKD Cohort.

Figure 2

Subjects with elevated cystatin C (>0.9 mg/dL) and TMAO (>3.4 μM) had the highest 5-year mortality risk in this non-CKD cohort (n=3,188).